Sam Chun Dang Pharm is making waves as a new Kosdaq leader, fueled by investor excitement surrounding its innovative drug pipeline, including advancements in oral insulin and a promising weight-loss pill.
On Thursday, shares closed at 1.16 million won ($770), marking a 3.86 percent increase and boosting the company’s market capitalization to 27.16 trillion won. Earlier in the day, the stock reached a peak of 1.19 million won, following its historic climb above the 1 million won mark the previous day – a feat last achieved by a Kosdaq-listed entity with EcoPro in 2023.
The stock’s ascent has been remarkable, more than quadrupling since the start of the year from 244,500 won on January 2nd. This growth is largely attributed to the high expectations surrounding its drug development programs.
The momentum gained significant traction in January when Sam Chun Dang Pharm announced a partnership with Daiichi Sankyo to collaborate on the development and commercialization of a weight-loss pill, specifically a generic version of oral semaglutide, the active ingredient in Wegovy.
Adding to the positive outlook, the company is also making significant strides in oral insulin research. Earlier this month, Sam Chun Dang Pharm announced its application to the European Medicines Agency to initiate Phase 1 and 2 clinical trials for its oral insulin candidate, SCD0503.
According to Korea Investment & Securities analyst Wi Hae-joo, “Success in this endeavor would represent a major breakthrough towards creating the world’s first oral insulin and could potentially revolutionize diabetes treatment.”
The stock’s upward trajectory has remained strong even after CEO Chun In-seok revealed plans to sell a 1.13 percent stake, reducing his ownership to 2.28 percent. In a letter addressed to shareholders, Chun clarified that the sale was intended to cover tax obligations and did not indicate any shift in management’s commitment. He also hinted at “significant news that could reshape the company’s standing” expected in the near future.
Despite the positive sentiment, valuation concerns are beginning to surface. The company’s substantial market capitalization, exceeding 27 trillion won, stands in contrast to its relatively modest financial performance last year, with reported revenue of 231.8 billion won and an operating profit of 8.5 billion won.
Furthermore, analyst coverage of the company remains limited. Korea Investment & Securities is currently the sole domestic brokerage that has published reports on Sam Chun Dang Pharm within the past year and has yet to issue a target price for the stock.
silverstar
